pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Melblez
drug · small molecule
save

melphalan hydrochloride

Marketedupdated 3mo ago
by $DCTH DELCATH SYSTEMS, INC.🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 investigational indications.

indications

investigational
Melanoma

all catalysts(0)

nothing on the calendar yet

Trials studying melphalan hydrochloride

  • phase4Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantationcompletedn=67
  • phase2Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patientsterminatedn=27

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 14, 2030
~4.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (11)

  • Jun 29, 2036formulationUS 10537520
  • Sep 17, 2034formulationUS 9707331
  • Feb 7, 2034formulationUS 9314561
  • Jan 16, 2033formulationUS 10195334
  • Dec 30, 2032formulationUS 11083831
  • Dec 30, 2032formulationUS 11833286
  • Nov 7, 2032formulationUS 10098997
  • Nov 7, 2032formulationUS 10369264
  • Nov 7, 2032method-of-use (U-3683)US 10569004
  • Nov 7, 2032formulationUS 11241522
  • Nov 7, 2032method-of-use (U-3675)US 11633528

FDA exclusivities (2)

  • Aug 14, 2030ODE-438Orphan Drug (7y)4.0y
  • Aug 14, 2026NPNP

News(0)

no news has mentioned this drug yet

brand
Melblez
trade names
Alkeran, Evomela, Hepzato, Ivra, Melphalan hydrochloride, Phelinun
generic
melphalan hydrochloride
indication
Bile Duct Cancer (Cholangiocarcinoma)
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?